IntelliCell BioSciences Announces That Dr. Steven Victor Was Thanked for His Work in Brain Trauma Research for Veterans
March 27 2014 - 9:00AM
Marketwired
IntelliCell BioSciences Announces That Dr. Steven Victor Was
Thanked for His Work in Brain Trauma Research for Veterans
NEW YORK, NY--(Marketwired - Mar 27, 2014) - IntelliCell
BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous vascular
cells (SVCs) derived from the blood vessels found in adipose
tissue, announced today that at the Stand For The Troops event in
Washington, D.C. last Saturday, March 23, Major General John
Batiste, US Army (Ret.) and Major Ben Richards, US Army (Ret.) the
brain trauma veteran who received his purple heart, thanked our
CEO, Steven Victor, MD for his help with brain trauma veterans.
IntelliCell BioSciences in collaboration with Dr. Sandlin Lowe
will be conducting investigational clinical protocol trials for
brain trauma in the near future. Veterans experiencing symptoms of
brain trauma are prime candidates for the study.
IntelliCell's Chief Executive Officer, Dr. Victor, remarked,
"This is a tremendous honor and it's a great feeling to know that
there is hope for a significant improvement in the quality of life
for these dedicated soldiers who suffer from brain trauma. We, at
IntelliCell, are excited to have this opportunity to work with the
distinguished neuropsychiatric, Dr. Lowe, and start investigational
clinical studies.
According to Eilhys England Hackworth, Co-Founder and Chair of
Stand For The Troops, "It was especially appropriate to open our
event, the first annual Bacon Brothers Concert with Major Ben
Richards, US Army (Ret.) receiving the Purple Heart from former
U.S. Army Vice Chief of Staff, General Peter Chiarelli. It was
equally appropriate to acknowledge and have present the two doctors
who treated Ben for his traumatic brain injury: Dr. Paul Harch, who
used hyperbaric oxygen and Dr. Steven Victor, who used autologous
stem cell therapy. Ben probably would not be able to comfortably
stand on stage to accept his purple heart without these pro bono
treatments from both of these doctors."
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell BioSciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. IntelliCell will
also be seeking to develop technology-licensing agreements with
technology developers, universities, and international business
entities.
About Stand For The Troops Soldiers For The Truth has become
Stand For The Troops. Our new name reflects exactly what we do on
behalf of all concerned Americans -- stand for the troops -- and
more specifically, stand for our frontline troops, our young heroes
who stand tall for us and our country out at the tip of the spear.
For more information go to: http://sftt.org/
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell BioSciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308